Richard Stone, MD, and Farhad Ravandi, MD
In this segment, “A Glimpse at the Future of AML”, Richard Stone, MD, and Farhad Ravandi, MD offer insights on emerging treatments and goals in AML (acute myeloid leukemia).
The recent approvals of the first targeted therapies for AML might be just the beginning. Additional targeted agents in late-stage clinical development include several new FLT3 inhibitors, novel BCL-2 inhibitors/pro-apoptotic agents, and others. Progress is also being made on the role of minimal residual disease in AML and potential interventions. Given the high level of research activity, it is expected that AML paradigms will continue to evolve in upcoming years.